Vanda Pharmaceuticals traded at $10.41 this Friday August 12th, increasing $0.11 or 1.07 percent since the previous trading session. Looking back, over the last four weeks, Vanda Pharmaceuticals gained 9.64 percent. Over the last 12 months, its price fell by 36.79 percent. Looking ahead, we forecast Vanda Pharmaceuticals to be priced at 10.12 by the end of this quarter and at 9.29 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
10.41
Daily Change
1.07%
Yearly
-36.79%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,801.00 3.00 0.08% 4.48%
Acadia Pharmaceuticals 16.40 0.66 4.19% -6.71%
Acorda Therapeutics 0.47 0.01 1.52% -86.93%
Agios Pharmaceuticals 28.15 2.16 8.31% -35.95%
Akebia Therapeutics 0.41 0.01 3.71% -83.60%
Alnylam Pharmaceuticals 233.85 4.46 1.94% 18.98%
Anika Therapeutics 22.38 0.64 2.94% -46.51%
Arrowhead Research 47.29 1.66 3.64% -21.86%
AstraZeneca 10,993.80 281.80 2.63% 29.69%
Bluebird Bio 6.72 0.41 6.50% -63.62%
Bristol-Myers Squibb 75.57 1.11 1.49% 11.94%
Clovis Oncology 1.48 0.03 2.07% -69.04%
Enanta Pharmaceuticals 67.99 1.50 2.26% 44.20%
Esperion Therapeutics 6.70 0.06 0.90% -51.83%
Halozyme Therapeutics 43.14 -0.22 -0.51% 4.03%
Heron Therapeutics 5.30 0.43 8.83% -52.04%
Intercept Pharmaceuticals 17.60 1.53 9.52% 17.96%
Insmed 27.26 0.51 1.91% 15.70%
J&J 165.30 -1.84 -1.10% -6.21%
Ligand Pharmaceuticals 106.36 4.39 4.31% -0.43%
Eli Lilly 308.08 6.91 2.29% 16.60%
Lexicon Pharmaceuticals 3.17 0.41 14.86% -12.67%
Merck & Co 91.02 2.09 2.35% 18.64%
Moderna Inc 171.18 -0.63 -0.37% -56.08%
Minerva Neurosciences 3.29 -0.10 -2.95% 94.67%
Novartis 85.68 0.10 0.12% -8.69%
Puma Biotechnology 3.51 -0.04 -1.13% -51.65%
Pfizer 50.11 1.82 3.77% 3.36%
PTC Therapeutics 52.75 0.74 1.42% 31.84%
Ultragenyx Pharmaceutical 51.57 0.32 0.62% -44.39%
Sanofi 85.47 0.01 0.01% -2.93%
Sangamo BioSciences 6.33 0.51 8.76% -37.01%
Teva Pharmaceutical Industries Ltd 3,604.00 -16.00 -0.44% 14.05%
Veracyte 26.05 0.56 2.20% -35.76%
Vanda Pharmaceuticals 10.41 0.11 1.07% -36.79%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.